Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3188908 | 0.92 | KIF11 (0.52) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6367386 | 0.87 | KIF11 (0.48) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL28263648 | 0.79 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3176030 | 0.78 | KIF11 (0.46) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL28583959 | 0.75 | KIF11 (0.50) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Iodide SCHEMBL8958390 | 0.74 | KIF11 (0.59) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1149158 | 0.74 | KIF11 (0.64) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9172228 | 0.73 | KIF11 (0.53) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9161414 | 0.73 | KIF11 (0.64) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9121213 | 0.71 | KIF11 (0.61) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198218-B2 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-06-12 | — | — | US | disclosed |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2010-01-28 | — | — | US | disclosed |
| EP-1461324-A4 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RES DEV CO (IL) | 2006-02-01 | — | — | EP | disclosed |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-12-01 | — | — | US | disclosed |
| EP-1461324-A2 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2004-09-29 | — | — | EP | disclosed |
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-31 | — | — | US | disclosed |
| WO-2003059876-A2 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144260-A1 | Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method | AADAC, ABCG2, HDAC3 | KIF11 3317/4885KCNH2 4134/4885CYP3A4 322/4885 |
| US-20100022499-A1 | HETEROCYCLIC COMPOUNDS, COMBINATORIAL LIBRARIES THEREOF AND METHODS OF SELECTING DRUG LEADS | AADAC, ABCG2, RICTOR | KIF11 3214/4885KCNH2 3619/4885CYP3A4 124/4885 |
| US-20050266496-A1 | Heterocyclic compounds, combinatorial libraries thereof and methods of selecting drug leads | AADAC, ABCG2, RICTOR | KIF11 3214/4885KCNH2 3619/4885CYP3A4 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.